Time Trends and Treatment Pathways in Prescribing Individual Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: An Observational Study of More than Three Million Patients from Europe and the United States.
Pareen VoraHenry Morgan StewartBeth RussellAlex AsiimweGunnar BrobertPublished in: International journal of clinical practice (2022)
From 2010 to 2017, VKA use had significantly declined and DOAC use had significantly increased in the US and Europe. Apixaban was the most prescribed OAC in 2017, followed by rivaroxaban.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- direct oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- end stage renal disease
- heart failure
- venous thromboembolism
- chronic kidney disease
- primary care
- percutaneous coronary intervention
- peritoneal dialysis
- ejection fraction
- prognostic factors
- pulmonary embolism
- emergency department
- coronary artery disease
- acute coronary syndrome
- adverse drug
- patient reported
- mitral valve
- smoking cessation